Dayan Victor, Grant Stuart W, Brophy James M, Barili Fabio, Freemantle Nick
Centro Cardiovascular Universitario, Cardiac Surgery Department, Hospital de Clinicas, Universidad de la Republica, Montevideo, Uruguay.
Division of Cardiovascular Sciences, University of Manchester, ERC, Manchester University Hospitals Foundation Trust, Manchester, UK.
Interdiscip Cardiovasc Thorac Surg. 2024 Jul 3;39(1). doi: 10.1093/icvts/ivae126.
Composite end points are common primary outcomes in clinical trials. Their main benefit of utilizing a composite outcome is increasing the number of primary outcome events, meaning fewer participants are required to deliver an adequately powered trial. By combining multiple important end points in the primary outcome rather than having to select only 1, composite end points potentially make clinically meaningful benefits easier to detect and avoid ranking outcomes hierarchically. However, there are a number of important considerations when designing and interpreting clinical trials that utilize composite end points. In this Statistical Primer, issues with composite end points such as competing events, halo effect, risk of bias, time-to-event limitations and the win ratio are discussed in the context of real world clinical trials.
复合终点是临床试验中常见的主要结局。使用复合结局的主要益处在于增加主要结局事件的数量,这意味着开展一项具有足够检验效能的试验所需的参与者数量更少。通过在主要结局中合并多个重要终点,而非仅选择一个,复合终点可能使具有临床意义的益处更易于发现,并避免对结局进行分层排序。然而,在设计和解读使用复合终点的临床试验时,有许多重要的考虑因素。在本统计入门中,将结合实际的临床试验来讨论复合终点的相关问题,如竞争事件、光环效应、偏倚风险、事件发生时间限制和获胜率。